The end of the blockbuster drug era; intense pressure from the generic sector; the rise of health management business models; counterfeit medicines; regulatory issues surrounding approval, pricing, repayment and patent protection; financing risky long - term investments - the challenges facing the life sciences sector have never been more numerous and complex.

The pharmaceutical, biotech and medical device businesses are searching for an economically sustainable business model while navigating a rapidly changing environment in which stakeholders such as shareholders, physicians, patients, payers and regulators are creating significant pressures for change. The industry needs a bold new vision and leaders who have the willingness to embrace a fundamentally new approach to their business.

Our life sciences leader, Thierry Vanwelkenhuyzen, shares his insights into this turbulent environment in the webcast below.